search
Back to results

Dietary Soy Isoflavones In Chronic Pancreatitis

Primary Purpose

Chronic Pancreatitis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Soy bread
Sponsored by
Ohio State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Pancreatitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosis of chronic pancreatitis by fulfilling one of the following clinical scenarios:

    1. Presence of pancreatic calcifications
    2. Suggestive for chronic pancreatitis - consistent EUS criteria or at least 3 abnormal side branches on pancreatic duct imaging
    3. Indeterminate EUS findings for chronic pancreatitis with evidence of exocrine pancreatic insufficiency (EPI)
  2. Age ≥18 years

Exclusion Criteria:

  1. Inability to provide written consent
  2. Inability to comply with the study protocol
  3. Soy allergy
  4. Pancreatic cancer
  5. History of prior pancreatic surgery (this does not include endoscopic therapies)
  6. Comorbid diseases characterized by a chronic inflammatory state, including, but not limited to rheumatologic diseases, chronic kidney disease, extra-pancreatic malignancy
  7. Pregnancy

Sites / Locations

  • Philip Hart

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Dose Escalation (DE) Phase

Maximum Tolerated Dose (MTD) Phase

Arm Description

Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.

After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.

Outcomes

Primary Outcome Measures

Dose Limiting Toxicities
Participants were evaluated for the development of bothersome symptoms that prevented them from being able to complete the recommended intervention course. Counts represent number of subjects who developed a symptom that prevented the ability to complete the dose/study period.

Secondary Outcome Measures

Pro-inflammatory Cytokines
Changes in the serum were assessed for TNF-alpha prior to and following introduction of soy bread

Full Information

First Posted
October 7, 2015
Last Updated
October 15, 2021
Sponsor
Ohio State University
search

1. Study Identification

Unique Protocol Identification Number
NCT02577640
Brief Title
Dietary Soy Isoflavones In Chronic Pancreatitis
Official Title
Dietary Soy Isoflavones In Chronic Pancreatitis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Dietary Soy Isoflavones in Chronic Pancreatitis: Investigating the Anti-inflammatory Effects of Food Innovation Science on Gastrointestinal Disease
Detailed Description
Management of pancreatic disorders imparts a major burden on healthcare costs, estimated at over 3 billion dollars annually. Chronic pancreatitis is characterized by chronic inflammation and progressive scarring, leading to abdominal pain, irreversible damage to the pancreas and the loss of both exocrine and endocrine function. Additionally, chronic pancreatic inflammation is a risk factor for pancreas cancer. There are no current treatments to modify the natural history of this disorder. Thus, identifying novel therapeutic options for this disease represents a high priority, and could fill an unmet medical need to improve quality of life, reduce risk of malignant transformation, and limit exorbitant medical costs associated with patient care. The investigators have assembled a multi-disciplinary research team to pursue an alternative, non-pharmacologic approach to limiting inflammatory cascades in (Chronic Pancreatitis) CP patients. They will assess compliance, toxicity and measure the changes in pro-inflammatory cytokine expression from a soy based dietary bread product using a classic 3+3 dose escalation study design in subjects with chronic pancreatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pancreatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dose Escalation (DE) Phase
Arm Type
Experimental
Arm Description
Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
Arm Title
Maximum Tolerated Dose (MTD) Phase
Arm Type
Experimental
Arm Description
After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
Intervention Type
Dietary Supplement
Intervention Name(s)
Soy bread
Other Intervention Name(s)
Soy Isoflavones
Intervention Description
Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
Primary Outcome Measure Information:
Title
Dose Limiting Toxicities
Description
Participants were evaluated for the development of bothersome symptoms that prevented them from being able to complete the recommended intervention course. Counts represent number of subjects who developed a symptom that prevented the ability to complete the dose/study period.
Time Frame
1 (dose escalation groups) or 4 (maximally tolerated dose) weeks
Secondary Outcome Measure Information:
Title
Pro-inflammatory Cytokines
Description
Changes in the serum were assessed for TNF-alpha prior to and following introduction of soy bread
Time Frame
1 (dose escalation group) or 4 weeks (maximally tolerated subject)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of chronic pancreatitis by fulfilling one of the following clinical scenarios: Presence of pancreatic calcifications Suggestive for chronic pancreatitis - consistent EUS criteria or at least 3 abnormal side branches on pancreatic duct imaging Indeterminate EUS findings for chronic pancreatitis with evidence of exocrine pancreatic insufficiency (EPI) Age ≥18 years Exclusion Criteria: Inability to provide written consent Inability to comply with the study protocol Soy allergy Pancreatic cancer History of prior pancreatic surgery (this does not include endoscopic therapies) Comorbid diseases characterized by a chronic inflammatory state, including, but not limited to rheumatologic diseases, chronic kidney disease, extra-pancreatic malignancy Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Hart, MD
Organizational Affiliation
The Ohio State Wexner Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Philip Hart
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32595109
Citation
Ahn-Jarvis J, Lombardo E, Cruz-Monserrate Z, Badi N, Crowe O, Kaul S, Komar H, Krishna SG, Lesinski GB, Mace TA, Ramsey ML, Roberts K, Stinehart K, Traczek M, Conwell DL, Vodovotz Y, Hart PA. Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study. Pancreatology. 2020 Jul;20(5):852-859. doi: 10.1016/j.pan.2020.04.018. Epub 2020 Jun 6.
Results Reference
background

Learn more about this trial

Dietary Soy Isoflavones In Chronic Pancreatitis

We'll reach out to this number within 24 hrs